Related Experiment Video
Updated: Jun 20, 2026
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Long-term Outcomes in Men with Stable PSA During 5-α Reductase Inhibitor Therapy After Negative Prostate Biopsy:
Eugenio Ventimiglia1, Marcus Westerberg1, Andri Wilberg Orasson1
1Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
European Urology Open Science
|June 19, 2026
Summary
Stable prostate-specific antigen (PSA) during 5-alpha reductase inhibitor (5-ARI) therapy after a negative biopsy indicates a very low risk of prostate cancer and related death. Further research is needed to determine if this finding impacts PSA surveillance intensity.
Area of Science:
- Urology
- Oncology
- Pharmacology
Background:
- Long-term outcomes after negative prostate biopsies, especially prostate cancer mortality, are not well-established.
- Optimal follow-up strategies for men with negative biopsies are unclear.
Related Concept Videos
01:20Disorders of the Male Reproductive System
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...